Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of adding oral hypoglycemic agents
(OHA) to existing insulin treatment in monogenic variant carriers of the Joslin 50-Year
Medalist Study ("Medalists"), who are characterized by ≥50 years of insulin-dependent
diabetes. Our primary objective is to evaluate whether the presence of human leukocyte
antigen (HLA) high-risk alleles for diabetes (DR3 and/or DR4) can affect the effectiveness of
OHA in these subjects.